These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. Ozolins M; Eady EA; Avery A; Cunliffe WJ; O'Neill C; Simpson NB; Williams HC Health Technol Assess; 2005 Jan; 9(1):iii-212. PubMed ID: 15588555 [TBL] [Abstract][Full Text] [Related]
29. Antibiotic-resistant Propionibacterium acnes among acne patients in a regional skin centre in Hong Kong. Luk NM; Hui M; Lee HC; Fu LH; Liu ZH; Lam LY; Eastel M; Chan YK; Tang LS; Cheng TS; Siu FY; Ng SC; Lai YK; Ho KM J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):31-6. PubMed ID: 22103749 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of VB-1953 Topical Gel in Non-Responder Acne Patients with Clindamycin-Resistant Cutibacterium acnes. Batra R; Sadhasivam S; Saini S; Gupta S; Bisen RKS; Sinha M; Ghosh S; Jain S Drugs R D; 2020 Jun; 20(2):95-104. PubMed ID: 32222937 [TBL] [Abstract][Full Text] [Related]
31. Antibiotic-resistant acne: lessons from Europe. Ross JI; Snelling AM; Carnegie E; Coates P; Cunliffe WJ; Bettoli V; Tosti G; Katsambas A; Galvan Peréz Del Pulgar JI; Rollman O; Török L; Eady EA; Cove JH Br J Dermatol; 2003 Mar; 148(3):467-78. PubMed ID: 12653738 [TBL] [Abstract][Full Text] [Related]
32. Antimicrobial susceptibility of Propionibacterium acnes isolated from acne vulgaris. Kurokawa I; Nishijima S; Kawabata S Eur J Dermatol; 1999; 9(1):25-8. PubMed ID: 9920982 [TBL] [Abstract][Full Text] [Related]
33. The bacteriology of acne vulgaris and antimicrobial susceptibility of Propionibacterium acnes and Staphylococcus epidermidis isolated from acne lesions. Nishijima S; Kurokawa I; Katoh N; Watanabe K J Dermatol; 2000 May; 27(5):318-23. PubMed ID: 10875198 [TBL] [Abstract][Full Text] [Related]
34. Antibiotic resistance of microbial strains isolated from Korean acne patients. Moon SH; Roh HS; Kim YH; Kim JE; Ko JY; Ro YS J Dermatol; 2012 Oct; 39(10):833-7. PubMed ID: 22779738 [TBL] [Abstract][Full Text] [Related]
35. Susceptibility of Cutibacterium acnes to topical minocycline foam. Sutcliffe J; McLaughlin R; Webster G; Read AF; Drlica K; Elliott R; Stuart I Anaerobe; 2020 Apr; 62():102169. PubMed ID: 32058277 [TBL] [Abstract][Full Text] [Related]
36. Heterogeneity and antibiotic resistance in Propionibacterium acnes isolates and its therapeutic implications: blurring the lines between commensal and pathogenic phylotypes. Sadhasivam S; Sinha M; Saini S; Kaur SP; Gupta T; Sengupta S; Ghosh S; Sardana K Dermatol Ther; 2016 Nov; 29(6):451-454. PubMed ID: 27424878 [TBL] [Abstract][Full Text] [Related]
37. A Myrtus communis extract enriched in myrtucummulones and ursolic acid reduces resistance of Propionibacterium acnes biofilms to antibiotics used in acne vulgaris. Feuillolay C; Pecastaings S; Le Gac C; Fiorini-Puybaret C; Luc J; Joulia P; Roques C Phytomedicine; 2016 Mar; 23(3):307-15. PubMed ID: 26969384 [TBL] [Abstract][Full Text] [Related]
38. Resistance of propionibacteria to antibiotics used in the treatment of acne. Brown JM; Poston SM J Med Microbiol; 1983 Aug; 16(3):271-80. PubMed ID: 6224016 [TBL] [Abstract][Full Text] [Related]